

Supporting information

Method development for effect-directed analysis of endocrine disrupting compounds in human amniotic fluid

Hanna M Dusza¹, Elwin Janssen², Rakesh Kanda³, Juliette Legler^{1,4*}

¹*Division of Toxicology, Institute for Risk Assessment Sciences, Faculty of Veterinary Medicine, Utrecht University, 3584 CM Utrecht, The Netherlands*

²*Institute for Molecules, Medicines and Systems, Department of Chemistry & Pharmaceutical Sciences, Vrije Universiteit Amsterdam, 1081 HZ Amsterdam, The Netherlands*

³*Institute of Environment, Health and Societies, Brunel University London, Uxbridge, UB8 3PH Middlesex, United Kingdom*

⁴*Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, 3584 CG Utrecht, The Netherlands*

* *Corresponding author at*

Institute for Risk Assessment Science

Faculty of Veterinary Medicine

Utrecht University

P.O. Box 80177, NL-3508 TD Utrecht

The Netherlands

Tel. +31 30 253 5217

Email: j.legler@uu.nl


28 **S1. – Chemicals**

29 α -Minimal Essential Medium (MEM) with GlutaMax (32561-029), Dulbecco's Modified
30 Eagle Medium/Nutrient Mixture F-12 medium (DMEM/F12) with GlutaMax (31331-028),
31 DMEM/F12 medium without phenol red (11880-028), Leibovitz's L-15 medium (L-15, 11415-
32 049), L-15 medium without phenol red (21083-027), Hank's Balanced Salt Solution (HBSS,
33 14175-053), penicillin/streptomycin (P/S, 15140-122), trypsin (25300-054) and foetal calf
34 serum (FCS) were purchased from Gibco (Eggenstein, Germany); G418 (ant-gn-1, ant-gn-5,
35 10832-42-2) was obtained from InvivoGen (Toulouse, France); Steady-Glo® Luciferase Assay
36 system (E2550) was purchased from Promega (Leiden, The Netherlands). Methanol (MeOH)
37 and dichloromethane (DCM) were purchased from Thermo Fisher Scientific (Loughborough,
38 UK); acetone was obtained from BDH Laboratory (Poole, Dorset, UK); dimethyl sulfoxide
39 (DMSO, 99.9+%) was obtained from Alfa Aesar (MA, USA). All solvents used were of HPLC
40 grade. Ammonium hydroxide solution (ACS reagent, 28.0-30.0% NH₃ basis) was purchased
41 from Sigma Aldrich (Poole, Dorset, UK); LC-MS grade water (LiChrosolv®) was obtained
42 from Merck KGaA (Darmstadt, Germany); chloroform (ACS reagent, 99.8+%) was purchased
43 from Acros Organics (Geel, Belgium). Two hydroxylated metabolites of brominated flame
44 retardants, namely 6-hydroxy-2,2',4,4'-tetrabromodiphenyl ether (6-OH-BDE-47) and 3-
45 hydroxy-2,2',4,4',5,5'-tetrabromodiphenyl ether (3-OH-BDE-153) were generously provided
46 by Dr. Lillemor Asplund (Stockholm University). All other reference compounds were
47 purchased from Sigma Aldrich (Poole, Dorset, UK) at the highest commercially available
48 purity. 4-methyl-2,4-bis(4-hydroxyl- phenyl) pent-1-ene (MBP), a potent metabolite of
49 bisphenol A, was synthesized and its identity and purity was confirmed spectrometrically
50 (NMR, IR and HR-MS) as described below.

51 S1.1 – Synthesis of 4,4'-(4-methylpent-1-ene-2,4-diyl)diphenol (MBP)

52 Materials and Methods: NMR spectra were recorded on a Bruker Avance 500 (125.78 MHz
53 for ^{13}C) using the residual solvent as internal standard (^1H : δ 2.05 ppm, $^{13}\text{C}\{^1\text{H}\}$: δ 206.26 ppm
54 for acetone- d_6 . Chemical shifts (δ) are given in ppm and coupling constants (J) are given in
55 Hertz (Hz). Melting points were recorded on a Büchi M-565 melting point apparatus.
56 Electrospray Ionization (ESI) high resolution mass spectroscopy was carried out using a Bruker
57 micrOTOF-Q instrument in negative ion mode. Infrared spectra were recorded neat using a
58 Shimadzu FTIR-8400s spectrophotometer and wavenumbers are reported in cm^{-1} . Flash
59 chromatography was performed on Silicycle Silia-P Flash Silica Gel (particle size 40-63 μm ,
60 pore diameter 60 Å) using the indicated eluent. Thin layer chromatographic (TLC) analysis
61 was performed with Merck F254 silica gel-60 and visualized by UV light.

62 4-Methyl-2,4-bis-(*p*-hydroxyphenyl)pent-1-ene (MBP): Bisphenol A (2.00 g, 8.76 mmol) was
63 dissolved in concentrated sulfuric acid (6.86 mL) and the orange solution was poured over ice
64 water (116 mL) under vigorous stirring. The resulting solids were collected by filtration. The
65 filtrate was washed with MTBE (3 x 20 mL) and the previously obtained solids were dissolved
66 in the combined organic layers. Traces of sulfuric acid in the organic layer were neutralized
67 with saturated aqueous NaHCO_3 , after which the organic layer was dried over Na_2SO_4 , filtered
68 and concentrated *in vacuo*. The residue was purified by flash silica gel chromatography
69 (gradient, CH_2Cl_2 :EtOAc 97.5:2.5 \rightarrow 90:10) to give MBP (235 mg, 20 %) as a white solid.


70 **Figure S1.1** - Proton NMR spectrum of synthesized MBP

71

72

73

^1H NMR: (500 MHz, Acetone- d_6) δ 8.16 (br s, 2H), 7.19 (ddd, 4H, J = 11.0 Hz, 9.0 Hz, 2.5 Hz), 6.74 (ddd, 4H, J = 11.0 Hz, 9.0 Hz, 2.0 Hz), 5.05 (d, 1H, J = 2.5 Hz), 4.68 (s, 1H), 2.78 (s, 2H), 1.17 (s, 6H);


74 **Figure S1.2** - ^{13}C NMR spectrum of synthesized MBP

75

76

77

^{13}C NMR: (125 MHz, Acetone- d_6) δ 157.5, 155.9, 147.4, 141.4, 135.7, 128.4 (2C), 127.6 (2C), 115.7 (2C), 115.3 (2C), 115.0, 50.1, 38.6, 29.4 (2C);

78 **Figure S1.3** - Infra Red (IR) spectrum of synthesized MBP


Comment:
EJA284

No. of Scans; 16
Resolution; 4[1/cm]
Apodization; Happ-Genzel

Date/Time; 14/12/2015 09:04:53
User; IR

79

80 IR (neat) ν_{max} (cm^{-1}): 3265 (s), 1610 (m), 1512 (s), 1437 (m), 1366 (m), 1221 (s), 1175 (s), 895 (m), 829 (s), 555 (s);

81 **Figure S1.4.** - HRMS (ESI) spectrum of synthesized MBP82
83
84
85

HRMS (ESI): m/z calculated for $C_{18}H_{19}O_2 [M-H]^-$ 267.1391, found 267.1403, $C_{18}H_{18}O_2 [M-2H]^{2-}$ 133.0659, found 133.0661; melting point 127.3-129.5 °C.

86
87
88
89**Table S1.** Concentration of the reference compounds in the spike mix used during method development of extraction and fractionation of amniotic fluid.

Compound	Concentration in the spike mix (µg/mL)
4-OP	0.788
PP	0.394
MnBP	0.708
BPA	0.570
BPS	0.679
MBP	0.336
TCS	0.423
OH-PCB-61	0.729
PFOS	0.263
6OH-BDE-47	0.378
3OH-BDE-157	0.741
daidzein	0.705
genistein	0.188
enterolactone	0.308
FICZ	0.345
E2	0.693
E1	0.292
E4	0.797

90

91 S2 - Extraction procedures

92 Solid phase extraction (SPE): MCX columns (Oasis, 6 cc, 150 mg/3 mL, 30 µm particle
93 size, Waters Corp., Milford, MA) and HLB columns (Oasis, 6 cc, 150 mg, 30 µm particle size,
94 Waters Corp., Milford, MA) were conditioned with 3 mL of methanol and 3 mL of deionised
95 water. Matrix (5ml of LC-MS grade water or AF) was spiked with the reference mix (100 µL),
96 pH was adjusted to 2 with 98% formic acid (for MCX extraction only), and then samples were
97 loaded on the cartridges at a rate of 1 mL/min. The MCX and HLB cartridges were rinsed with
98 3 mL of 2% formic acid (in deionized water) and with 5% methanol respectively, and then air
99 dried for 1 min. The analytes were eluted from the MCX cartridges with 2 x 2 mL of 100%
100 methanol and 2 x 2 ml of 5% of ammonium hydroxide, and from the HLB cartridges with 4 x
101 2ml of 100% methanol. Deionised water (0.2 mL) was added to the extracts and the extracts
102 put in a water bath (max. temperature 40°C) where the solvent was evaporated under a gentle
103 stream of nitrogen to a final volume of 0.2 mL. The samples were then reconstituted with 0.3
104 mL of 10% methanol in deionised water, transferred to glass vials for analysis and analysed on
105 LC-ESI-MS/MS for chemical recoveries.

106 Dispersive liquid/liquid extraction (DLLE): 5 ml of LC-MS grade water or amniotic
107 fluid was spiked with the reference mix (100 µL) and pH adjusted to ~4.5 with sodium
108 acetate/acetic acid buffer (0.1 M). DLLE was performed by addition of DCM (0.5 mL) or
109 chloroform (0.5 mL) only, or by addition of a mixture of acetone (1ml) (dispersive solvent)
110 and DCM (0.5 mL) or chloroform (0.5 mL) (extraction solvent). Samples were then vortexed
111 2 x for 15 seconds and centrifuged at 4081 x g for 15 min at 25°C. The supernatant was
112 removed, 50 µL of deionised water was added, the organic layer evaporated under gentle
113 stream of nitrogen and the residue reconstituted with 10% MeOH to a final volume of 0.5 mL.
114 Samples were transferred to glass vials and analysed on LC-ESI-MS/MS for chemical
115 recoveries.

116 **Table S2.** Parameters used during LC-ESI-MS/MS Multiple Reaction Monitoring (MRM) detection of the
 117 analytes including collision cell parameters and monitored precursor/product ions. Limit of detection (LOD)
 118 for each analyte was calculated as described in the method section.

Compound	Q1	Q3a	Q3b	DT	EP	DP (Q/C)	CE (Q/C)	CXP (Q/C)	LOD (M)
4-OP	205.18	106.0	189.0	25	-10	-55	-28	-15	4.4 x 10 ⁻¹⁰
PP	179.13	91.9	136.0	25	-10	-55	-32	-13	6.0 x 10 ⁻¹¹
MnBP	221.05	121.1	70.9	25	-12	-80	-20	-13	2.0. x 10 ⁻¹⁰
BPA	227.20	133.1	212.0	25	-11	-90/-90	-40/-26	-13/-13	3.7 x 10 ⁻⁰⁹
BPS	249.10	107.9	156.0	25	-10	-70	-38	-17	3.7 x 10 ⁻¹¹
MBP	267.20	133.1	117.2	25	-11	-100/-150	-25/-50	-13/-15	9.4 x 10 ⁻¹²
TCS	287.09	34.9	241.1	25	-10	-40	-48	-7	5.4 x 10 ⁻¹¹
OH-PCB-61	306.95	270.8	34.9	25	-10	-55/-55	-30/-82	-19/-17	9.9 x 10 ⁻¹¹
PFOS	498.95	79.9	98.9	25	-10	-170	-84	-17	9.9 x 10 ⁻¹²
6OH-BDE-47	500.75	78.8	80.8	25	-10	-75	-40	-11	2.7 x 10 ⁻¹¹
3OH-BDE-157	658.55	80.8	576.6	25	-10	-105/-105	-100/-38	-13/-41	5.8 x10 ⁻¹²
daidzein	253.14	132.0	223.0	25	-10	-90/-90	-54/-36	-7/-13	1.7 x 10 ⁻¹¹
genistein	269.10	133.1	63.1	25	-10	-135/-135	-46/-50	-11/-11	2.9 x 10 ⁻¹¹
enterolactone	297.16	253.0	107.0	25	-10	-110/-150	-28/-50	-17/-15	2.7 x 10 ⁻¹¹
FICZ	283.30	254.2	255.3	25	-10	-90	-40	-13	2.1 x 10 ⁻¹¹
E2	271.15	183.0	145.0	25	-10	-80/-50	-56/-56	-11/-17	4.1 x 10 ⁻¹¹
E1	269.12	145.0	142.9	25	-10	-105	-52	-23	1.6 x 10 ⁻¹¹
E4	303.12	241.0	273.0	25	-14	-90	-28	-15	3.8 x 10 ⁻¹¹

119 Q1, precursor ion (m/z); Q3a, quantification product ion (m/z); Q3b, confirmation product ion (m/z); DT, dwell time
 120 (ms); DP, declustering potential (V); EP, entrance potential (V); CE, collision energy (V); CXP, collision cell exit
 121 potential (V)

122 S3 – Cell culture

123 The estrogen receptor-mediated luciferase reporter gene (ER-Luc) human breast
124 carcinoma (VM7Luc4E2) cells¹, the androgen/glucocorticoid receptor-mediated luciferase
125 reporter gene (AR-Luc) human breast carcinoma (MDA-kb2) cells² and the aryl hydrocarbon
126 receptor enhanced green fluorescent protein reporter gene (DR-GFP) mouse hepatoma
127 (H1G1.1c3) cells³ were routinely maintained in 75 cm² canted neck tissue culture flasks
128 (Greiner Bio-One Ltd.). ER-Luc and DR-GFP cells were maintained in DMEM/F12 and α -
129 MEM medium respectively, supplemented with 10% FCS and 1% P/S (culture media) and
130 incubated in a humidified incubator at 37 °C and 5% CO₂. DR-GFP cells were additionally
131 supplemented with 1% G418. AR-Luc cells were maintained in Leibowitz-15 (L-15) medium
132 supplemented with 10% FCS (culture media) and incubated in a humidified incubator at 37 °C
133 without additional CO₂. Cells were subcultured when 70-80% confluent.

134

135 *ER, AR and DR reporter gene assays*

136 *ER-Luc*: Prior to experiments, ER-Luc cells were maintained in DMEM/F12 medium
137 without phenol red (assay media) supplemented with 10% charcoal dextran stripped FCS
138 (cdFCS) and 1% P/S for two media-changes (4 days). Cells were seeded at a density of 2x10⁴
139 cells per well in 100 μ L of assay media in clear-bottomed 96-well tissue culture dishes (Greiner
140 Bio-One Ltd.) and allowed to attach. After 24 h media was removed and 100 μ L of assay media
141 containing test chemicals or DMSO control (0.5%) was added to the wells. After 24h of
142 exposure, media was removed, cells washed with PBS (200 μ L), PBS removed and lysis buffer
143 added (20 μ L). After cell lysis (15 min with shaking) the luciferase activity was determined in
144 a plate reader (LUMIstar Optima, BMG Labtech GmbH) with 100 μ L of luciferase reagent
145 media injected directly to each well during measurement.

146 *AR-Luc*: Prior to experiments, AR-Luc cells were maintained in L-15 medium
147 supplemented with 10% cdFCS (pre-assay media) for two media-changes (4 days). Cells were
148 then seeded at a density of 2×10^4 cells per well in 100 μ L of phenol red-free L-15 medium
149 supplemented with 10% cdFCS (assay media) into white, clear-bottomed 96-well tissue culture
150 dishes and allowed to attach. After 24 h, 100 μ L assay medium was added to the wells with
151 twice the intended final concentration of test chemicals or DMSO control (0.5%), to obtain the
152 desired test concentrations. After 24 h of exposure, 100 μ L of media was removed and
153 SteadyGlo assay reagent (Promega UK Ltd.) (100 μ L) was added to the wells and the plate left
154 shaking for 10 min. The luciferase activity was determined as described above.


155 *DR-GFP*: DR-Luc cells were maintained in culture media and when confluent seeded
156 in black, clear-bottomed 96-well tissue culture dishes (DR-Luc) (Greiner Bio-One Ltd.) in
157 MEM Alpha media supplemented with 10% FCS, 1% P/S, but without addition of G418 (assay
158 media). Cells were seeded at a density of 3×10^4 cells per well in 100 μ L of assay media and
159 left to attach. After 24 h, media was aspirated and cells exposed to test chemical or DMSO
160 control (1%) in 100 μ L of assay media. After 24 h of exposure, fluorescence was measured in
161 the intact cells (without removal of media) using a fluorescent plate reader (POLARstar
162 Galaxy, BMG Labtech GmbH) with an excitation wavelength and an emission wavelength set
163 at 485 nm and 510 nm, respectively. In order to normalize results the fluorescence gain was
164 adjusted per plate to the highest activity of the positive control. In each assay the outer wells
165 of the plate were not included in the measurements and were filled with 100 μ L assay media
166 only.

167 Cell viability was determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
168 tetrazolium bromide (MTT). Briefly, after 23 h exposure, media was removed from each well,
169 100 μ L of 5 mg/ml freshly made MTT solution was added and plates were incubated at 37 °C.
170 At $t = 24$ h, MTT solution was removed, lysis buffer (150 μ L of isopropanol) was added to the

171 wells and the plate left shaking for 15 min. The absorbance at ($\lambda_{ex} = 590$ nm) was measured

172 with a POLARstar fluorescent plate reader.

173



174

175

176

177

178

179

180

181

182

183

184


185

186

187

188

Figure S2. The $\log P$ of reference compounds retrieved from PubChem database (www.pubchem.ncbi.nlm.nih.gov) plotted against retention times (RT) during RP-HPLC fractionation of spiked AF extract, including estrol (E4), 17 β -estradiol (E2) estrone (E1) and bisphenol A (BPA). $\log P$ of estriol (E3), androstenedione (ASD), dihydrotestosterone (DHT) and testosterone was plotted against their predicted RTs interpolated from linear regression analysis (GraphPad Software Inc., San Diego, CA).



189

190

191

192

193

194

195

Figure S3. An example of a chromatogram obtained during reversed-phase fractionation of AF extract. Sample was injected onto reverse phase Phenomenex Kinetex C18 (100mm x 2.1 mm, 5 μ m pore size) column using an Agilent 1260 system equipped with diode array detector (DAD). Absorbance was monitored with a 253 nm wavelength and plotted against retention time. Eluted fractions were concentrated, resuspended in DMSO and used for bioassay analysis.

196
197




Figure S4. Agonistic activity of AF fractions (50 x diluted) in the ER-Luc assay. ER activity was measured as described in the method section (n=1).

198
199
200
201

202

203

204 References

205 (1) Rogers, J. M.; Denison, M. S. Recombinant Cell Bioassays for Endocrine Disruptors: Development of a
206 Stably Transfected Human Ovarian Cell Line for the Detection of Estrogenic and Anti-Estrogenic
207 Chemicals. *In Vitro. Mol. Toxicol.* **2000**, *13* (1), 67–82.

208 (2) Wilson, V. S.; Bobseine, K.; Lambright, C. R.; Gray, L. E. A Novel Cell Line, MDA-Kb2, That Stably
209 Expresses an Androgen- and Glucocorticoid-Responsive Reporter for the Detection of Hormone
210 Receptor Agonists and Antagonists. *Toxicol. Sci.* **2002**, *66* (1), 69–81.
211 <https://doi.org/10.1093/toxsci/66.1.69>.

212 (3) Nagy, S. R.; Sanborn, J. R.; Hammock, B. D.; Denison, M. S. Development of a Green Fluorescent
213 Protein-Based Cell Bioassay for the Rapid and Inexpensive Detection and Characterization of Ah
214 Receptor Agonists. *Toxicol. Sci.* **2002**, *65* (2), 200–210. <https://doi.org/10.1093/toxsci/65.2.200>.

215